Temenuzhka Mihaylova

Temenuzhka Mihaylova

Auto-generated profile, based on publicly available information

Temenuzhka Mihaylova

Department of Neurology, University of Michigan, 1500 E. Medical Center Dr., Ann Arbor, 48109-1079, United States

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
GXGang Xu
Gang Xu
TMTemenuzhka Mihaylova
Temenuzhka Mihaylova
DLDuan Li
Duan Li
FTFangyun Tian
Fangyun Tian
PFPeter M. Farrehi
Peter M. Farrehi
JBJimo Borjigin
Jimo Borjigin
The brain is assumed to be hypoactive during cardiac arrest. However, animal models of cardiac and respiratory arrest demonstrate a surge of gamma oscillations and functional connectivity. To investigate whether these preclinical findings translate to humans, we analyzed electroencephalogram and electrocardiogram signals in four comatose dying patients before and after the withdrawal of ventilatory support. Two of the four patients exhibited a rapid and marked surge of gamma power, surge of cross-frequency coupling of gamma waves with slower oscillations, and increased interhemispheric functional and directed connectivity in gamma bands. High-frequency oscillations paralleled the activation of beta/gamma cross-frequency coupling within the somatosensory cortices. Importantly, both patients displayed surges of functional and directed connectivity at multiple frequency bands within the posterior cortical “hot zone,” a region postulated to be critical for conscious processing. This gamma activity was stimulated by global hypoxia and surged further as cardiac conditions deteriorated in the dying patients. These data demonstrate that the surge of gamma power and connectivity observed in animal models of cardiac arrest can be observed in select patients during the process of dying.

7 August 2018 in Journal of Electrocardiology
Verified
Journal Article
Closed access
PDF file
GXGang Xu
Gang Xu
SDSneha Dodaballapur
Sneha Dodaballapur
TMTemenuzhka Mihaylova
Temenuzhka Mihaylova
JBJimo Borjigin
Jimo Borjigin

10 May 2024 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
VPVineet Punia
Vineet Punia
PKPavel Klein
Pavel Klein
TMTemenuzhka Mihaylova
Temenuzhka Mihaylova
VBVictor Biton
Victor Biton
OSOmar Samad
Omar Samad
MMManoj Malhotra
Manoj Malhotra
ELEVATE (Study 410; NCT03288129) is the first prospective, multicenter, open-label, Phase IV study of perampanel as monotherapy or first adjunctive therapy in patients aged ≥ 4 years with focal-onset seizures or generalized tonic–clonic seizures in the United States. The study included Screening, Titration (≤ 13 weeks), Maintenance (39 weeks), and Follow-up (4 weeks) Periods. During Titration, perampanel was initiated at 2 mg/day and up-titrated to 4 mg/day at Week 3. Depending on response and tolerability, optional up-titrations to a maximum of 12 mg/day occurred. The primary endpoint was retention rate; additional endpoints included seizure-freedom rate, 50% responder rate, and incidence of treatment-emergent adverse events (TEAEs). At baseline, 10 (18.5%) patients were assigned to the monotherapy group and 44 (81.5%) patients to the first adjunctive therapy group. However, due to the addition of an anti-seizure medication along with perampanel on the first day of treatment, one patient was excluded from the monotherapy subgroup analyses. The mean perampanel exposure duration was 39.8 weeks and 32 (59.3%) patients completed the study. Retention rate at 12 months (or study completion) was 63.0% (monotherapy, 77.8%; first adjunctive therapy, 59.1%). Seizure-freedom rate during the Maintenance Period was 32.7% (monotherapy, 44.4%; first adjunctive therapy, 29.5%) and the 50% responder rate was 78.7% (monotherapy, 85.7%; first adjunctive therapy, 76.9%). TEAEs and serious TEAEs were reported by 88.9% (n = 48/54) and 7.4% (n = 4/54) of patients, respectively. Overall, the efficacy and safety of perampanel as monotherapy or first adjunctive therapy support the use of perampanel as early-line treatment for epilepsy.

12 March 2026 in Journal of Neural Engineering
Verified
Journal Article
Open access
STShi Bei Tan
Shi Bei Tan
SGStephen V Gliske
Stephen V Gliske
NJNeha Sara John
Neha Sara John
WKWesley Kerr
Wesley Kerr
TMTemenuzhka Mihaylova
Temenuzhka Mihaylova
WSWilliam C Stacey
William C Stacey
Objective. High frequency oscillations (HFOs) are a promising biomarker of epilepsy, but automated detectors have significant risk for false positives due to diverse EEG artifacts. Many of these artifacts, previously uncharacterized in HFO research, are readily visible to clinicians under standard EEG viewing conditions. We present an artifact detector trained on clinician markings that identify when HFOs were produced by artifacts. Approach. Clinicians read standard resolution (10 sec per screen, all channels visible, 0-30 Hz), intracranial EEG with 8,000 HFO events marked in 35 patients. They labeled each event as brain-derived or artifactual based upon their expert interpretation of the EEG at the time of the event, creating a new gold standard of HFO labeling. We used 4,000 events for training/validation and 4,000 for held-out prospective testing. We extracted features at the time of the HFOs from the single intracranial HFO channel and the scalp and intracranial common average reference, then trained candidate supervised learning classifiers to distinguish artifacts and non-artifactual HFOs (naHFOs). Main results. The resulting Michigan Intracranial Artifact Filter (MIAF) uses binary logistic regression on just intracranial data at the time of the HFO detection to remove false positives. The MIAF applied on held-out patient data significantly increased positive predictive value from 86% to 98% and resulted in an area under the precision recall curve and receiver operating characteristic curve of 99% and 92% respectively. It improved the correlation between HFOs and the seizure onset zone and resected volume in 76.5% and 88.9% of patients respectively, outperformed alternative artifact detectors, and allowed HFO analysis from all states of vigilance. Significance. MIAF effectively removes false positives HFO detections while retaining sufficient naHFOs for downstream analysis. Because it relies only on raw intracranial data during HFO detections, it can be easily ported to other HFO detectors and recording environments.